NDA 203094 · Gilead Sciences INC
Tybost
Cobicistat · Oral · Cytochrome P450 3A Inhibitor
OrphanDiscontinuedLast checked: Nov 20, 2026Latest source record: Jun 20, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Sep 24, 2014
Approved uses
8
Original approval plus efficacy supplements
Registered trials
155
48 Phase 3, 6 recruiting
FAERS reports
621
582 serious, 64 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 10, 2026.
TYBOST is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection in adults and in pediatric patients weighing at least 14 kg. ( 1.1 ) Limitations of Use : TYBOST is not interchangeable with ritonavir to increase systemic exposure of darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir due to lack of exposure data. The use of TYBOST is not recommended with darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir. ( 1.2 , 5.4 ) Complex or unknown mechanisms of drug interactions preclude extrapolation of ritonavir drug interactions to certain TYBOST interactions. TYBOST and ritonavir when administered with either atazanavir or darunavir may result in different drug interactions when used with concomitant medications. ( 1.2 , 5.3 , 7 , 12.3 ) 1.1 Indications Adult Patients: TYBOST is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection in adults [see Dosage and Administration (2.1) ]. Pediatric Patients: TYBOST is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection in pediatric patients weighing at least 14 kg [see Dosage and Administration (2.2) , and Drug Interactions (7.3) ]. 1.2 Limitations of Use TYBOST is not interchangeable with ritonavir to increase systemic exposure of darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir due to lack of exposure data. The use of TYBOST is not recommended with...
Mechanism: Cobicistat is a mechanism-based inhibitor of cytochrome P450 3A (CYP3A). Inhibition of CYP3A-mediated metabolism by cobicistat increases the systemic exposure of CYP3A substrates atazanavir and darunavir.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 20, 2025 Supplement 17 · Efficacy OrphanLabelLetter
- Jun 20, 2025 Supplement 18 · Efficacy OrphanLabelLetter
- Oct 3, 2019 Supplement 14 · Efficacy · priority review OrphanLabelLetter
- Aug 22, 2019 Supplement 13 · Efficacy · priority review OrphanLetterLabelPediatric CDTL Review
- Oct 30, 2018 Supplement 12 · Efficacy · priority review LabelLetter
- Nov 25, 2015 Supplement 3 · Efficacy LabelLetter
- Sep 24, 2014 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
- Sep 24, 2014 Original approval · Efficacy
2 products under this application
- TYBOST · COBICISTAT 150MG · TABLET, ORAL · Discontinued · TE AB
- TYBOST · COBICISTAT 90MG · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Cobicistat" as an intervention, any sponsor and status, largest first.
- RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled InfectionPivotal-lookingStatus unknown
A.O. Ospedale Papa Giovanni XXIIIAcademic, hospital or other
NCT04064632 · 1,609 participants · Start Feb 1, 2017 · Primary completion Jun 13, 2019
Drug: Rilpivirine + darunavir/cobicistat · For: HIV Infection
Sites: Bergamo, Italy
- Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive ParticipantsPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01815736 · 1,443 participants · Start Mar 27, 2013 · Primary completion Mar 16, 2015
Drug: E/C/F/TAF; E/C/F/TDF and 5 more · For: HIV; HIV Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 167 sites in all
Janssen R&D IrelandJohnson & Johnson (Janssen) (JNJ)
NCT02269917 · 1,149 participants · Start Mar 2015 · Primary completion Feb 2017
Drug: D/C/F/TAF; Boosted Protease Inhibitor (bPI) and 1 more · For: Human Immunodeficiency Virus Type 1
Sites: Phoenix, Arizona; Bakersfield, California; Beverly Hills, California · 79 sites in all
- Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive AdultsPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01797445 · 872 participants · Start Mar 12, 2013 · Primary completion Sep 19, 2014
Drug: E/C/F/TAF; E/C/F/TDF and 2 more · For: HIV; HIV Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 117 sites in all
- Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive AdultsPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01780506 · 872 participants · Start Dec 26, 2012 · Primary completion Aug 26, 2014
Drug: E/C/F/TAF; E/C/F/TDF and 2 more · For: HIV; HIV Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 117 sites in all
Janssen Sciences Ireland UCJohnson & Johnson (Janssen) (JNJ)
NCT02431247 · 725 participants · Start Jul 6, 2015 · Primary completion Mar 2, 2017
Drug: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC; DRV/COBI FDC and 4 more · For: Immunodeficiency Virus Type 1, Human
Sites: Birmingham, Alabama; Phoenix, Arizona; Bakersfield, California · 80 sites in all
- Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01106586 · 708 participants · Start Apr 2010 · Primary completion Sep 2011
Drug: Stribild; ATV and 6 more · For: HIV; HIV Infections
Sites: Phoenix, Arizona; Little Rock, Arkansas; Beverly Hills, California · 146 sites in all
- Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01095796 · 707 participants · Start Mar 2010 · Primary completion Aug 2011
Drug: Stribild; Atripla and 2 more · For: HIV; HIV Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 102 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug interaction181
- cushing^s syndrome60
- foetal exposure during pregnancy48
- immune reconstitution inflammatory syndrome38
- serotonin syndrome36
- adrenal insufficiency32
- off label use29
- anxiety26
- drug ineffective25
- pain25
- virologic failure24
- emotional distress22
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2012 | 2 |
| 2013 | 5 |
| 2014 | 13 |
| 2015 | 11 |
| 2016 | 37 |
| 2017 | 33 |
| 2018 | 44 |
| 2019 | 83 |
| 2020 | 82 |
| 2021 | 41 |
| 2022 | 80 |
| 2023 | 61 |
| 2024 | 60 |
| 2025 | 50 |
| 2026 | 18 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tybost (Cobicistat)
2024 spending
$270K
Beneficiaries
144
750 claims
Per beneficiary
$1,873
$9.80 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $233,323 |
| 2021 | $241,059 |
| 2022 | $248,359 |
| 2023 | $266,480 |
| 2024 | $269,682 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.
Ryan P, Blanco JL, Masia M, et al. · Lancet HIV 2025 · Multicenter Study, Randomized Controlled Trial
- Symtuza® in clinical practice.
Luis Casado J, Fontecha M, Monsalvo M, et al. · Enferm Infecc Microbiol Clin (Engl Ed) 2018 · Clinical Trial, Phase III
- Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study).
Overbeek JK, Guchelaar NAD, Mohmaed Ali MI, et al. · Eur J Cancer 2023 · Randomized Controlled Trial, Multicenter Study
- The Drug-Drug Interaction Profile of Presatovir.
Xin Y, Weng W, Murray BP, et al. · J Clin Pharmacol 2018 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Population Pharmacokinetics of Boosted-Elvitegravir in HIV-Infected Patients.
Custodio JM, Gordi T, Zhong L, et al. · J Clin Pharmacol 2016 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis.
Gantner P, Hessamfar M, Souala MF, et al. · Clin Infect Dis 2020 · Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: Gilead Sciences
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.